Kornimate/medical-research-clean huggingface dataset:
the effect of acute and chronic exercise at the metabolic syndrome and markers of inflammation in obese subjects

Conditions: Obesity; Healthy

Summary: the human adipose and muscle -tissue produce and release a number of bioactive proteins which contributes to the chronic low grade of inflammatory status which is associated with obesity and plays an important role in the pathogenesis of type 2 diabetes and cardiovascular diseases. study 1: our aim is to investigate if exercise has independent and additive effects in combination with diet-induced weight loss on circulating levels of inflammatory markers and mrna levels in subcutaneous adipose tissue (sat) and skeletal muscle tissue (sm. study 2: our aim is to investigate whether gender and weight status plays a role in the metabolic response during two hours of acute exercise


Eligibility criteria:
inclusion criteria: * age 18-45 years, * obese (30 kg/m2 \< bmi \< 40 kg/m2) physically inactive (\<30 minutes pr. day) * and weight stabile for at least three months (± 2 kg of current body weight) exclusion criteria: * cardiovascular disease, * type 2 diabetes, pregnancy or orthopaedic difficulties causing inability to undertake an exercise program

Keywords: obese adults
impact of mayoexpertadvisor on provider adherence

Conditions: Hyperlipidemia; Atrial Fibrillation; Heart Failure

Summary: this study evaluates the efficacy of mayoexpertadvisor (mea), a knowledge delivery tool, to improve adherence to best practices for patients with hyperlipidemia, atrial fibrillation and heart failure. half of the clinicians will receive mea, while the other half will not receive mea. the investigators hypothesize care teams with access to mea will act upon recommendations at a higher rate than those care teams in the standard of care arm without access to mea.

mea is designed to increase adherence to consensus national guidelines and quality measures which are the standard of care for hyperlipidemia, atrial fibrillation, and heart failure. these diseases were selected based on national data which suggest there is less than optimal adherence to standard of care therapy and this non-adherence is associated with adverse cardiovascular outcomes. there are 29 care teams in the employee and community health (ech) practice. care teams are comprised of 4-8 clinicians who provide primary care to between 3,000 and 8000 patients. 8 care teams are resident/fellow led and will be excluded from the study. the remaining 21 care teams in the ech practice will be stratified by clinic location and provider specialty (internal medicine, family medicine). 20 care teams will then be cluster-randomized to either the intervention arm or standard of care arm. prior to randomization, clinicians in both arms will receive the same educational module to the current guidelines for management of the atrial fibrillation, heart failure and hyperlipidemia. clinicians in the intervention arm will receive training by the research team on the use of mea. this training will clearly inform clinicians that they are always to use their best clinical judgment.

Eligibility criteria:
clinician inclusion criteria: * physicians * assistants * nurse practitioners clinician exclusion criteria: * clinicians providing care to nursing home patients * pediatricians * residents and fellows patient record inclusion criteria: * diagnosis of hyperlipidemia, atrial fibrillation, and/or heart failure patient record exclusion criteria: * unscheduled visits
quantifying the venous congestion curve of a tissue oximetry device

Conditions: Post-Op Complication; Skin Flap Necrosis

Summary: the purpose of this research study is to measure rate of decline and pattern of tissue oxygenation using the device, vioptix t.ox. vioptix probes will be secured to the arm and hand. the recording process on the vioptix machine will begin and obtain baseline sto2 levels for 5 minutes. after 5 minutes, a blood pressure cuff will be inflated on one arm. this blood pressure cuff will be left inflated for 10-20 minutes. every 2 minutes a pulse check or doppler exam will be performed at your wrist. last, the cuff will be deflated and the you will be free to leave the study room.

the rate of decline and pattern seen in tissue oxygenation as quantified by a nirs device (vioptiox t.ox) can be quantified and described by a mathematical model which will allow earlier detection and identification of venous congestion in tissue. the vascular occlusion test has been established as a safe and accurate model to induce various states of vascular insufficiency and occlusion. specifically the vascular occlusion test has been demonstrated to be an accurate model for inducing venous insufficiency on awake and aware patients. this study will aim to analyze the sto2 data output of the vioptix in order to establish the earliest signs of tissue failure in various states of vascular compromise. the purpose of this research study is to measure rate of decline and pattern of tissue oxygenation using the device, vioptix t.ox. the data collected will be used to formulate a mathematical model which will allow earlier detection and identification of venous congestion in tissue. identifying these specific patterns will help to establish an evidence-based approach in recognizing specific problems and patterns associated with tissue compromise that can guide physicians to consider earlier flap salvage measures.

Eligibility criteria:
inclusion criteria: * age 18 - 65 volunteers exclusion criteria: * subjects with a history of major cardiac disease, peripheral vascular disease including (vascular insufficiency), raynaud syndrome, blood dyscrasias, pain syndromes, neurologic conditions, major upper extremity soft tissue trauma or previous vascular injury
study on the role of hormonal treatment for two dosage levels of prostate radiation therapy versus prostate radiation therapy alone

Conditions: Prostate Cancer

Summary: the hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with irradiation, the investigators could reduce local failure rates for these two dosage levels, namely 70 gy and 76 gy. since increasing the dose to the prostate also seems to reduce local relapse rates, the results of the two hormonal therapy groups would be compared with the results of prostate irradiation at doses of 76 gy. this study would verify the possibility of compensating a six gy dosage increase of radiation therapy with six months of hormonal therapy between the 70 gy and 76 gy groups who received hormonal therapy, and also match these results with a dose escalation to the prostate of 76 gy. in the future, this could result in more therapeutic choices, such as reducing the doses of radiation therapy and, consequently, its related complications, if hormonal therapy proves to be beneficial; or rather, to continue in the direction of dose escalation for this intermediate-risk patient group, everything being correlated to the side effects of hormonal therapy and irradiation.


Eligibility criteria:
inclusion criteria: * patients with stage t1 or t2 untreated adenocarcinoma of the prostate, with a gleason score that is less than or equal to 6, as well as a prostate-specific antigen (psa) between 10-20 (intermediate risk) or patients with stage t1 or t2 untreated adenocarcinoma of the prostate, with a gleason score that is equal to 7, as well as a psa equal to or less than 20 (intermediate risk). * performance status score of 0-1 * patients must sign a consent form before starting the study. * no evidence of regional disease * patients with a previous history of cancer are eligible on the condition that they have been disease-free for more than five years. * non-invasive epidermoid cancers of the skin are eligible. * the patient must be available for treatments and follow-up visits. * no evidence of metastatic disease, confirmed by a negative bone scan. exclusion criteria: * severe medical or psychiatric problems that may compromise study compliance * chronic hepatic disease; abnormal hepatic function, i.e. aspartate aminotransferase and alanine aminotransferase \> 1.5 times the upper normal limit.

Keywords: prostate adenocarcinoma gleason score <= 6 and psa 10-20 gleason score = 7 and psa <=20
stage-based exercise promotion study

Conditions: Obesity; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to increase regular physical activity among students by fostering self-management competencies. the intervention was implemented as paper-pencil intervention. the aim of this research project is to evaluate a motivational and volitional intervention in comparison to a control intervention. study participants will be recruited in lectures at freie universitaet berlin and followed up twice (two and ten weeks after baseline). the motivational intervention is expected to increase unmotivated participants' intention to be physically active. the volitional intervention is expected to promote physical activity among motivated but inactive participants. both interventions are hypothesized to improve self-management competencies over time.

an experimental study is planned over a time period of ten weeks. in the physical activity study, participants will randomly be allocated to either one of two intervention groups (ig) or to an active control group (acg), receiving a quiz on physical activity and sports. intervention group 1 receives a paper-pencil intervention which focuses on positive outcome expectancies (motivational intervention). intervention group 2 receives a paper-pencil intervention which promotes the formulation of action plans for physical activity (volitional intervention). furthermore, all participants will receive two emails as intervention boosters until the end of the study. study participants will be invited to take part in the study during lectures of the freie universitaet berlin. the students will be followed up twice: two weeks after t1 (paper-pencil), t2 will take place (paper-pencil). eight weeks after t2 the t3 assessment will be conducted online. the hypotheses are: participants of the motivational intervention report a larger increase in motivation to adopt physical activity from t1 to t2 and t3, as compared to the participants of the volitional or the control intervention. effects will be larger in unmotivated participants than in already motivated participants. participants of the volitional intervention report a larger increase in physical activity from t1 to t2 and t3, as compared to the participants of the motivational or the control intervention. effects will be larger in motivated participants than in unmotivated participants.

Eligibility criteria:
inclusion criteria: * to be capable of exercising on their own at a minimum level * able to fill out a questionnaire (no illiteracy) * adequate german language ability exclusion criteria: * no internet access * no email address

Keywords: action planning positive outcome expectancies randomized controlled trial stages of change health behavior motivation
evaluating the effectiveness of art therapy on mood, anxiety, and pain levels in cancer patients

Conditions: Cancer

Summary: participants in this research study are asked to tell about their experience with art therapy. participants in this research study are currently receiving chemotherapy treatment for cancer. the purpose of this study is to learn how art therapy affects mood, anxiety, pain, and emotions of individuals with cancer who are undergoing chemotherapy.

in this single-center single-arm non-controlled descriptive study, we aim to describe the effects of a single art therapy session on a cancer patient's mood, pain, anxiety level. primary objectives * to assess the effect of art therapy on the cancer patient's mood * to assess the effect of art therapy on the cancer patient's anxiety * to assess the effect of art therapy on the cancer patient's pain secondary objectives * to explore differences in response to art therapy by ethnic group, race, age, sex, caregiver support, cancer diagnosis, reason for visit, and marital status * to explore differences in response to art therapy by primary concern expressed by patients during art therapy sessions

Eligibility criteria:
inclusion criteria: * subjects are able to give informed consent * any cancer diagnosis * actively undergoing any chemotherapy treatment at maroone cancer center * patients who have never utilized art therapy at maroone cancer center * speaks, reads, and writes in english * able and willing to participate in an art therapy session at maroone cancer center exclusion criteria: * patients without cancer diagnosis * patients not actively undergoing chemotherapy at maroone cancer center * individuals unable to complete art therapy activities independently due to physical and/or mental impairment * under 18 years of age (minors) * patients who have dementia or a legal guardian * unable to speak, read, and write in english * patients who have previously utilized art therapy at maroone cancer center

Keywords: art therapy chemotherapy
fecal microbiota transplantation for irritable bowel syndrome

Conditions: Irritable Bowel Syndrome; Fecal Microbiota Transplantation

Summary: fecal microbiota transplantation (fmt) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome. fmt has a higher cure rate than standard antibiotic treatment for recurrent clostridium difficile infections,and shows promising results in inflammatory bowel disease（ibd）.however, few studies have evaluated whether fmt is effective to treat irritable bowel syndrome(ibs).the investigators propose to determine the efficiency and safety of fmt in patients with irritable bowel syndrome.

the present clinical trial aims to re-establish a gut functionality state of intestinal flora through fmt as a therapy for irritable bowel syndrome(ibs). we established a standard microbiota isolation from donated fresh stool in lab. then the microbiota is transplanted to the whole colon through a tube. patients from guangzhou first people's hospital in this study will be assigned to receive fmt at least two times according to associated guidelines and follow-up for at least six months. questionnaires will be used to assess participants at study start and at study completion.

Eligibility criteria:
inclusion criteria: to be considered eligible for enrolment into the study, subjects must: * be able to give written informed consent. * males and females aged \>18 and \<75 * have ibs as defined by the rome iv criteria exclusion criteria: subjects will be excluded from the study if they meet any of the below criteria: * pregnant or having a follow-up of less than 6 months; * unable to give informed consent; * suffering from other severe disease ,including liver and kidney failure, cancers, intestinal diseases, inflammatory bowel disease, c difficile infection; * unable to undergo endoscopy.
a study to investigate whether the immediate use or deferred use of an anti-viral drug lamivudine will help to better safe-guard the delivery of chemotherapy in patients with cancer who are also hepatitis b carriers

Conditions: Hepatitis B; Neoplasms

Summary: patients with non-lymphoma and non-leukaemia cancer who are also hepatitis b carriers will have a risk of hepatitis b reactivation during chemotherapy. lamivudine can be used effectively to control hepatitis upon reactivation during chemotherapy and the chemotherapy may not need to be interrupted. the study aims to investigate whether adding the anti-viral drug lamivudine at the start of chemotherapy for all patients, rather than at the time of hepatitis reactivation for those with reactivation, will help to improve the delivery of chemotherapy in these patients.


Eligibility criteria:
inclusion criteria: 1. patient with histology-proven malignant solid tumor other than malignant lymphoma 2. patients with age between 18 and 75 3. patients with karnofsky performance score (kps) of at least 60 4. patients planned for at least 4 cycles of intensive cytotoxic chemotherapy (either as part of curative therapy or as palliative therapy), except for those receiving single agent cisplatin chemotherapy alone concurrently with radiation for radiosensitization 5. patients with at least 6 months' life expectany from date of recruitment 6. patients with normal liver function tests including alanine aminpotransferase (alt), alkaline phosphatase (alp), gamma glutamyl-transpeptidase (ggt), and bilirubin 7. patients with no known history of radiological \&/or histological diagnosis of chronic active hepatitis or cirrhosis of any cuase, or history of prior hepatitis b reactivation, or prior chronic therapy for hbv within 6 months 8. patients with no evidence of autoimmune hepatitis, hepatitis c or delta virus infection, hiv infection or radiological evidence of liver metastasis 9. patients with negative pregnancy test for female gender of child-bearing age exclusion criteria: 1. patients with age \ 75 2. patients with karnofsky performance score (kps) of \< 60 3. patients planned for single agent cisplatin chemotherapy alone concurrently with radiation for radiosensitization 4. patients with \< 6 months' life expectancy from date of recruitment 5. patients with abnormal liver function tests including alanine aminotransferase (alt), alkaline phosphatase (alp), gamma glutamyl- transpeptidase (ggt), and bilirubin 6. patients with known history or radiological and/or histological diagnosis of chronic active hepatitis or cirrhosis of any cause, or history of prior hepatitis b reactivation, or prior chronic therapy for hbv within 6 months 7. patients with autoimmune hepatitis, hepatitis c or delta virus infection, hiv infection or radiological evidence of liver metastasis 8. pregnant female patients

Keywords: hepatitis b during cancer chemotherapy
10-propargyl-10-deazaaminopterin plus probenecid in treating patients with advanced solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. probenecid may increase the effectiveness of 10-propargyl-10-deazaaminopterin by making tumor cells more sensitive to the drug. purpose: phase i trial to study the effectiveness of combining 10-propargyl-10-deazaaminopterin and probenecid in treating patients who have advanced solid tumors.

objectives: * determine the maximum tolerated dose of 10-propargyl-10-deazaaminopterin and probenecid in patients with advanced solid tumors. * determine the therapeutic activity of this regimen in these patients. * determine the toxic effects of this regimen in these patients. * determine the pharmacokinetics of this regimen in these patients. outline: this is a dose-escalation study of 10-propargyl-10-deazaaminopterin (pdx) and probenecid. patients receive probenecid iv and pdx iv on day 1. treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. cohorts of 3-6 patients receive sequentially escalating doses of probenecid and pdx until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. projected accrual: a total of 35-40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed cancer that is potentially incurable by standard chemotherapy, radiotherapy, or surgical procedures * failed prior first-line therapy (patients are also eligible if no effective first-line therapy exists) * previously treated or clinically stable brain metastases are allowed * no leukemia or lymphoma * no clinically significant pleural effusions or ascites patient characteristics: age: * 18 and over performance status: * karnofsky 70-100% life expectancy: * not specified hematopoietic: * wbc at least 4,000/mm\^3 * platelet count at least 160,000/mm\^3 * hemoglobin greater than 10 g/dl * serum and rbc folate normal hepatic: * bilirubin no greater than 1.5 mg/dl * sgot or sgpt less than 2 times upper limit of normal renal: * creatinine no greater than 1.2 mg/dl or * creatinine clearance at least 60 ml/min cardiovascular: * no unstable angina * no congestive heart failure * no cardiac arrhythmia other: * homocysteine normal * no grade iii or iv edema * not pregnant or nursing * fertile patients must use effective contraception during and for 6 months after study prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics * at least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas or mitomycin) and recovered endocrine therapy: * not specified radiotherapy: * see disease characteristics * at least 3 weeks since prior radiotherapy to bone marrow-containing areas and recovered surgery: * see disease characteristics * no prior pneumonectomy other: * no concurrent folic acid or potentially nephrotoxic agents

Keywords: unspecified adult solid tumor, protocol specific
study to evaluate the analgesic efficacy and safety of intravenous paracetamol in subjects with postoperative pain after total hip arthroplasty

Conditions: Pain

Summary: the main purpose is to evaluate the analgesic efficacy of 1g of intravenous (iv) paracetamol versus i.v. placebo, administered every 6h, as measured by the reduction of the 24-hour cumulative dose of the opioid tramadol in the treatment of postoperative pain following total hip arthroplasty.


Eligibility criteria:
inclusion criteria: * spinal anesth * bmi 10-35 * no pain conditions/concom med may alter pain quantif. exclusion criteria: * other add. surgery * liver/renal function altered * coagulation alterations * respir / cardiac insufficiency * agents affecting microsomal syst

Keywords: subjects with postoperative pain after total hip arthroplasty
establish the benefits of using various starting doses of atorvastatin on achievement of cholesterol targets (actfast)

Conditions: Coronary Arteriosclerosis; Diabetes Mellitus, Type 2; Cerebrovascular Accident; Dyslipidemia; Peripheral Vascular Disease

Summary: physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. the study evaluates if selecting the starting dose based on baseline and target ldl-c cholesterol would provide better results (ie proportion of subjects resching target)


Eligibility criteria:
inclusion criteria: * high cholesterol blood levels (ldl-cholesterol above 100 mg/dl up to 220 mg/dl. * triglycerides up to 600 mg/dl. * history of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events exclusion criteria: * pregnancy or lactation, use of high statin doses (\>40mg) at baseline, liver or renal problems, use of other drugs that would interfere with evaluation of efficacy or cause safety problems, uncontrolled hypertension, diabetes or hypothyroidism, recent cardiac event of procedure, high baseline cpk levels